# A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction

> **NCT00203476** · PHASE4 · COMPLETED · sponsor: **Tuscaloosa Research & Education Advancement Corporation** · enrollment: 30 (actual)

## Conditions studied

- Hyperlipidemia
- Hypercholesterolemia

## Interventions

- **DRUG:** Niacin
- **DRUG:** Colestipol
- **DRUG:** Ezetimibe

## Key facts

- **NCT ID:** NCT00203476
- **Lead sponsor:** Tuscaloosa Research & Education Advancement Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203476, "A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00203476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*